Giant-cell tumor of bone

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search
Section editor
Elizabethdavis2.jpg
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN

Social-twitter-icon.png ejdavis25
1 regimens on this page
1 variants on this page


All lines of therapy

Denosumab monotherapy

back to top

Regimen

Study Years of enrollment Evidence
Thomas et. al 2010 (Amgen 20040215) 2006-2008 Phase II (RT)
Chawla et al. 2013 (Amgen 20062004) 2008-2011 Phase II (RT)

Targeted therapy

  • Denosumab (Xgeva) as follows:
    • Cycle 1: 120 mg SC once per day on days 1, 8, 15
    • Cycle 2 onwards: 120 mg SC once on day 1

Supportive medications

  • Calcium 500 mg PO once per day
  • Vitamin D 400 IU PO once per day

28-day cycles

References

  1. Amgen 20040215: Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. Epub 2010 Feb 10. link to original article contains verified protocol PubMed
  2. Amgen 20062004: Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. link to original article contains protocol PubMed
    1. Update: Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. link to original article PubMed